MoonLake Immunotherapeutics
MLTX13.830USD
-0.040-0.29%
收盘 12/26, 16:00（美东）报价延迟15分钟
881.03M总市值
亏损市盈率 TTM
关于 MoonLake Immunotherapeutics 公司
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics简介
公司代码MLTX
公司名称MoonLake Immunotherapeutics
上市日期Oct 20, 2020
CEOSantos Da Silva (Jorge)
员工数量100
证券类型Ordinary Share
年结日Oct 20
公司地址Dorfstrasse 29
城市ZUG
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Switzerland
邮编6300
电话41415108022
网址https://moonlaketx.com/
公司代码MLTX
上市日期Oct 20, 2020
CEOSantos Da Silva (Jorge)
MoonLake Immunotherapeutics公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月1日 周一
更新时间: 12月1日 周一
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
其他
54.61%
持股股东
持股股东
占比
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
其他
54.61%
股东类型
持股股东
占比
Hedge Fund
47.09%
Individual Investor
9.25%
Investment Advisor
6.20%
Investment Advisor/Hedge Fund
5.92%
Research Firm
1.10%
Venture Capital
0.49%
Bank and Trust
0.10%
Pension Fund
0.04%
其他
29.81%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Bodenstedt (Matthias)
616.67K
0.97%
--
--
Mar 15, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
占比0.27%
Global X Guru Index ETF
占比0.22%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.02%
Strive Small-Cap ETF
占比0.02%
Nuveen ESG Small-Cap ETF
占比0.02%
iShares Morningstar Small-Cap ETF
占比0.01%
John Hancock Multifactor Small Cap ETF
占比0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
占比0.01%
Fidelity Nasdaq Composite Index ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
MoonLake Immunotherapeutics的前五大股东是谁？
MoonLake Immunotherapeutics 的前五大股东如下：
BVF Partners L.P.持有股份：19.75M，占总股份比例：31.10%。
Santos da Silva (Jorge)持有股份：3.08M，占总股份比例：4.85%。
Reich (Kristian)持有股份：3.13M，占总股份比例：4.93%。
Avoro Capital Advisors LLC持有股份：4.15M，占总股份比例：6.54%。
Cormorant Asset Management, LP持有股份：1.99M，占总股份比例：3.14%。
BVF Partners L.P.持有股份：19.75M，占总股份比例：31.10%。
Santos da Silva (Jorge)持有股份：3.08M，占总股份比例：4.85%。
Reich (Kristian)持有股份：3.13M，占总股份比例：4.93%。
Avoro Capital Advisors LLC持有股份：4.15M，占总股份比例：6.54%。
Cormorant Asset Management, LP持有股份：1.99M，占总股份比例：3.14%。
MoonLake Immunotherapeutics的前三大股东类型是什么？
MoonLake Immunotherapeutics 的前三大股东类型分别是：
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
有多少机构持有MoonLake Immunotherapeutics(MLTX)的股份？
截至2025Q3，共有336家机构持有MoonLake Immunotherapeutics的股份，合计持有的股份价值约为52.26M，占公司总股份的73.22%。与2025Q2相比，机构持股有所增加，增幅为-38.84%。
哪个业务部门对MoonLake Immunotherapeutics的收入贡献最大？
在--，--业务部门对MoonLake Immunotherapeutics的收入贡献最大，创收--，占总收入的--%。
